I - NEUROPACE, N O V E M B E R 2 0 2 1 Personalized, data-driven treatment for epilepsy 1 Disclaimer | 2 In addition to background and historical information, this presentation contains "forward-looking statements" based on NeuroPace's current expectations, estimates, forecasts and beliefs, including information about NeuroPace's market opportunity, commercial strategy, growth, FDA approvals, future pipeline, product performance, indication and TAM Expansion Opportunities, expectations for hiring, clinical ...

NeuroPace, Inc. (NASDAQ:NPCE) Q3 2021 Earnings Conference Call November 10, 2021 4:30 PM ET Company Participants Matt Bacso - Investor Relations Mike Favet - Chief Executive Officer Rebecca Kuhn - Chief Financial Officer Conference Call Participants Robbie Marcus - JPMorgan Drew Ranieri - Morgan Stanley Danielle Antalffy - SVB Leerink Michael Polark - Baird Disclaimer*: This transcript is designed to be used alongside the freely available audio recording on this page. Timestamps within the transcript are de ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number 001-40337 NEUROPACE, INC. (Exact name of registrant as specified in its charter) Washington, D.C. 20549 FORM 10-Q (Mark One) (State or other jurisdiction of incorporation or or ...

NeuroPace, Inc. (NASDAQ:NPCE) Q2 2021 Earnings Conference Call August 12, 2021 4:30 PM ET Company Participants Matt Bacso - Investor Relations Mike Favet - Chief Executive Officer Rebecca Kuhn - Chief Financial Officer Conference Call Participants Drew Ranieri - Morgan Stanley Danielle Antalffy - SVB Leerink Operator Good morning and welcome to NeuroPace???s Second Quarter Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded for replay purposes. I would now like to tu ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number 001-40337 NEUROPACE, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organiz ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number 001-40337 NEUROPACE, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organi ...

NeuroPace, Inc. (NASDAQ:NPCE) Q1 2021 Earnings Conference Call June 3, 2021 8:00 AM ET Company Participants Matt Bacso ??? Gilmartin Group Mike Favet ??? Chief Executive Officer Rebecca Kuhn ??? Chief Financial Officer Conference Call Participants Robbie Marcus ??? JPMorgan Drew Ranieri ??? Morgan Stanley Larry Biegelsen ??? Wells Fargo Danielle Antalffy ??? SVB Leerink Operator Good morning and welcome to NeuroPace???s First Quarter Earnings Conference Call. At this time, all participants are in listen-onl ...